Seqens Supports EU Anti-Dumping Probe into Chinese Acetylsalicylic Acid Imports

The European Commission has initiated an anti-dumping investigation into imports of acetylsalicylic acid (ASA) originating in China. SEQENS says it supports open trade and fair competition on a level playing field, and it will fully cooperate with the Commission throughout the process. The company describes ASA as a critical pharmaceutical ingredient used in Aspirin and other essential healthcare applications, and it has long prioritised a competitive European manufacturing base for key active pharmaceutical ingredients.

Key facts

Market context

Acetylsalicylic acid, better known as aspirin's active ingredient, is a widely used active pharmaceutical ingredient for pain relief, fever reduction, and cardiovascular preventive therapy. Demand is driven mainly by generic and over-the-counter medicine manufacturers and by public healthcare systems that buy large volumes of low-cost essential medicines, so pricing tends to be sensitive to import competition. When an authority opens an anti-dumping investigation, buyers typically watch for changes in import volumes, possible duties on the origin country, and shifts in how contracts are sourced between Asian producers and European manufacturers. Such probes can take months to conclude, and outcomes often depend on evidence about pricing and injury to domestic producers. In the meantime, importers and formulators may diversify suppliers or hold extra inventory, which can tighten availability and affect quoted prices for ASA across the European market.

Source: official release on seqens.com. Summary and context written by Market Krystal.